Marinomed Biotech AG has successfully completed its announced capital increase. GBC Kapital GmbH supported the transaction and thereby accompanied an important financing step for a listed biotechnology company in the German-speaking region. Marinomed is listed under ISIN: ATMARINOMED6 and WKN: A2N9MM. 

With the successful completion of the capital measure, Marinomed strengthens its financial base and creates the conditions for its next operational and strategic development steps. The financing particularly supports the company’s further development as well as its positioning in the ongoing commercialization discussions relating to its lead products Budesolv and Tacrosolv. 

The successful execution of the transaction underlines the capital market’s confidence in Marinomed, the company’s technology platform and its further corporate development. For Marinomed, the completion of the capital increase represents an important step in strengthening its financial flexibility. 

By supporting the Marinomed transaction, GBC Kapital GmbH builds on another successfully executed financing step from recent months. In December 2025, GBC Kapital also accompanied the full placement of the 2026/2029 convertible bond of A.H.T. Syngas Technology N.V. with a total nominal amount of EUR 2.0 million. The company is listed under ISIN NL0010872388 and WKN A12AGY. 

“We are pleased to have supported Marinomed in this important financing step. The successfully implemented capital increase sends a positive signal and creates a strengthened basis for the company’s next development steps. At the same time, the successful placement of the convertible bond of A.H.T. Syngas Technology N.V. in December 2025 also demonstrates our ability to support companies with tailored financing solutions,” said Marcus Blask, Head of Sales of GBC Kapital GmbH.

The inclusion of the new shares in trading on the Vienna Stock Exchange is expected to take place after completion of the usual formal steps. 

About Marinomed Biotech AG

Marinomed Biotech AG is an Austrian, science-based biotechnology company with a growing development pipeline. The company develops patented, innovative products based on its Marinosolv® platform. The Marinosolv® technology increases the solubility and bioavailability of poorly soluble active ingredients and is used for the development of new therapeutics for indications in the field of autoreactive immune diseases. The company is headquartered in Korneuburg, Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). Further information: https://www.marinomed.com.

About GBC Kapital GmbH

GBC Kapital GmbH, based in Augsburg, specializes in supporting capital market transactions as well as equity and debt financing solutions for mid-sized and listed companies. The company supports issuers in addressing qualified investors and accompanies financing projects with capital markets expertise and an established investor network.

Recent transactions supported by GBC Kapital include, in addition to the successful capital increase of Marinomed Biotech AG, the full placement of the 2026/2029 convertible bond of A.H.T. Syngas Technology N.V. (ISIN: NL0010872388, WKN: A12AGY) in December 2025. 

On the internet: www.gbc-kapital.de